TIMELINE MANAGEMENT STRATEGIES: ENABLING DEVELOPING COUNTRIES TO DELIVER COMPLEX GENERICS TO GLOBAL MARKETS
DOI:
https://doi.org/10.22159/ijap.2026v18i1.53438Keywords:
Complex generics, Developing countries, Timeline management, Pharmaceutical industry, Generic drug development, Project management, Regulatory compliance, Bioequivalence, Organizational culture, Workforce psychologyAbstract
This review analyzes effective project timeline management strategies for complex generic drug development in developing countries, addressing challenges like regulatory inefficiencies, limited infrastructure, and workforce constraints. It provides actionable recommendations to align product development with financial and organizational goals in resource-constrained settings. The paper highlights the growing role of developing countries in the global generics market and examines challenges specific to complex generics. It traces the evolution of timeline management from traditional methods to advanced project management tools, which have reduced development cycle times by 20-30% in adopting organizations. Key factors such as organizational size, workforce psychology, and cultural contexts are analyzed, with strategies to mitigate their impact on timelines. The review emphasizes establishing meaningful milestones, coordinating cross-functional activities, and addressing emerging challenges. It underscores the need to synchronize milestones across organizational, financial, and product factors, adapting lessons from established countries to developing nations. A multifaceted approach integrating regulatory expertise, advanced project management tools, and financial planning is proposed to overcome technical and regulatory hurdles while ensuring financial sustainability and market responsiveness. By adopting these principles, enterprises in developing countries can enhance their ability to supply high-quality generic medicines, improving healthcare accessibility and outcomes. The review aims to equip policymakers and pharmaceutical companies with actionable insights for optimizing development timelines, improving regulatory compliance, and enhancing cross-functional coordination.
References
1. Globe Newswire. Generic drugs market size worth US $728.64 bn by 2034, driven by affordability, patent expirations and government support. 2025 Apr 16. Available from: https://www.globenewswire.com/news-release/2025/04/16/3062706/0/en/genericdrugs‑market‑size‑worth‑728‑64‑bn‑by‑2034‑driven‑by‑affordability‑patent‑expirations‑and‑government‑support.html.
2. Demina NB, Bakhrushina EO, Anurova MN, Merkushova AG, Pomytkina MV, Rastopchina OV. Complex generics as a trend of modern pharmaceutical development. Int J App Pharm. 2024;16(3):71-7. doi: 10.22159/ijap.2024v16i3.49937.
3. Stern S, Coghlan JP, Krishnan V, Raney SG, Babiskin A, Jiang W. Research and education needs for complex generics. Pharm Res. 2021 Dec;38(12):1991-2001. doi: 10.1007/s11095-021-03149-y, PMID 34950975.
4. Panchal K, Katke S, Dash SK, Gaur A, Shinde A, Saha N. An expanding horizon of complex injectable products: development and regulatory considerations. Drug Deliv Transl Res. 2022;13(2):433-72. doi: 10.1007/s13346-022-01223-5, PMID 35963928.
5. Market F. Insights complex generics market. Available from: https://www.futuremarketinsights.com/reports/complex-genericsmarket#:~:text=The%20complex%20generics%20market%20is,affordable%2C%20high-complexity%20treatments. [Last accessed on 18 Jun 2025].
6. Walenga RL, Babiskin AH, Zhao L. In silico methods for development of generic drug device combination orally inhaled drug products. CPT Pharmacometrics Syst Pharmacol. 2019;8(6):359-70. doi: 10.1002/psp4.12413, PMID 31044532, PMCID 6618094.
7. Renukuntla J, Palakurthi SS, Bolla PK, Clark BA, Boddu SH, Manda P. Advances in in vitro bioequivalence testing methods for complex ophthalmic generic products. Int J Pharm. 2022;627:122209. doi: 10.1016/j.ijpharm.2022.122209, PMID 36162609.
8. Haider R. The role and impact of generics in pharmaceutical markets. JDD. 2024 May 6;9(3):1-5. doi: 10.31579/2578-8949/155.
9. Klein K, Borchard G, Shah VP, Fluhmann B, McNeil SE, De Vlieger JS. A pragmatic regulatory approach for complex generics through the US FDA 505(j) or 505(b) (2) approval pathways. Ann N Y Acad Sci. 2021;1502(1):5-13. doi: 10.1111/nyas.14662, PMID 34296458.
10. Ranbaxy. Ranbaxy announces launch of atorvastatin generic Lipitor® in the US; 2011 Dec 01. Available from: https://www.daiichisankyo.com/media/press_release/detail/index_3727.html. [Last accessed on 18 Jun 2025].
11. Shaikh R, Yadav K, Thummar K, Maheriya B, Chauhan S. Development of complex generics: insights into trends challenges and market opportunities. J Generic Med. 2025;21(1):4-16. doi: 10.1177/17411343251313962.
12. Ranjan R. Development of complex generics and similar biological products: an industrial perspective of reverse engineering. AAPS PharmSciTech. 2025 Mar 26;26(4):95. doi: 10.1208/s12249-025-03087-7, PMID 40140232.
13. Rajput A, Pillai M, Ajabiya J, Sengupta P. Integrating quantitative methods and modeling and analytical techniques in reverse engineering; a cutting-edge strategy in complex generic development. AAPS PharmSciTech. 2025 Mar 26;26(4):92. doi: 10.1208/s12249-025-03067-x, PMID 40140161.
14. Lunawat S, Bhat K. Complex generic products: insight of current regulatory frameworks in US EU and Canada and the need of harmonisation. Ther Innov Regul Sci. 2020 Sep;54(5):991-1000. doi: 10.1007/s43441-020-00114-6, PMID 31960290.
15. Klein K, Stolk P, De Bruin ML, Leufkens HG, Crommelin DJ, De Vlieger JS. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: observations and recommendations. Eur J Pharm Sci. 2019 May 15;133:228-35. doi: 10.1016/j.ejps.2019.03.029, PMID 30953753.
16. Rocco P, Musazzi UM, Franze S, Minghetti P. Copies of nonbiological complex drugs: generic hybrid or biosimilar. Drug Discov Today. 2019 Jan;24(1):250-5. doi: 10.1016/j.drudis.2018.08.003, PMID 30086403.
17. Kuribayashi R, Goto K, Ogawa T. Trend analysis of regulatory approvals for generics and biosimilars in Japan: 15 y of PMDA during fiscal years 2009-2023. AAPS J. 2024 Nov 12;26(6):113. doi: 10.1208/s12248-024-00989-5, PMID 39532822.
18. Zagalo DM, Simoes S, Sousa J. Regulatory science approach in pharmaceutical development of follow on versions of non-biological complex drug products. J Pharm Sci. 2022 Oct;111(10):2687-713. doi: 10.1016/j.xphs.2022.07.015, PMID 35901943.
19. Hussaarts L, Muhlebach S, Shah VP, McNeil S, Borchard G, Fluihmann B. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks. Ann N Y Acad Sci. 2017 Nov;1407(1):39-49. doi: 10.1111/nyas.13347, PMID 28445611.
20. Zaidi FB, Ahmed SE, Makkad M. Role of effective project management in reducing drug development cost. Asian J Pharm Clin Res. 2017 Mar 1;10(3):53. doi: 10.22159/ajpcr.2017.v10i3.16186.
21. Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine learning and artificial intelligence in pharmaceutical research and development: a review. AAPS J. 2022 Jan 1;24(1):19. doi: 10.1208/s12248-021-00644-3, PMID 34984579.
22. Dave CV, Sinha MS, Beall RF, Kesselheim AS. Estimating the cost of delayed generic drug entry to medicaid. Health Aff (Millwood). 2020 Jun;39(6):1011-7. doi: 10.1377/hlthaff.2019.00673, PMID 32479219.
23. Chorniy A, Bailey J, Civan A, Maloney M. Regulatory review time and pharmaceutical research and development. Health Econ. 2021 Jan;30(1):113-28. doi: 10.1002/hec.4180, PMID 33078483.
24. Wang Y, Li J, Anupindi R. Manufacturing and regulatory barriers to generic drug competition: a structural model approach. SSRN Journal. 2018;69(3):1323-34. doi: 10.2139/ssrn.3145635.
25. Kamusheva M, Turcu Stiolica A, Gierczynski J, Subtirelu MS, Czech M, Petrova G. Do advanced therapies have a future in the low and middle income countries the case of Bulgaria Romania and Poland. Front Public Health. 2021 Aug 23;9:729847. doi: 10.3389/fpubh.2021.729847, PMID 34497796.
26. Olaghere J, Williams DA, Farrar J, Buning H, Calhoun C, Ho TW. Scientific advancements in gene therapies: opportunities for global regulatory convergence. Biomedicines. 2025;13(3):758. doi: 10.3390/biomedicines13030758, PMID 40149734.
27. Fu X, Buckley PJ, Sanchez Ancochea D, Hassan I. The world has a unique opportunity: accelerating technology transfer and vaccine production through partnerships. J Int Bus Policy. 2021 Nov 10;5(3):406-15. doi: 10.1057/s42214-021-00124-7.
28. Ahonkhai VI, Martins SF, Portet A, Lumpkin M, Hartman D. Speeding access to vaccines and medicines in low and middle-income countries: a case for change and a framework for optimized product market authorization. PLOS One. 2016 Nov 16;11(11):e0166515. doi: 10.1371/journal.pone.0166515, PMID 27851831, PMCID 5112794.
29. Beierle J, Algorri M, Cortes M, Cauchon NS, Lennard A, Kirwan JP. Structured content and data management enhancing acceleration in drug development through efficiency in data exchange. AAPS Open. 2023 May 8;9(1):11. doi: 10.1186/s41120-023-00077-6, PMID 37193559.
30. Albrecht M, Hoer A, Zimmermann A. Value of generic medicines: an health economics study. J Pharm Policy Pract. 2015 Oct 5;8(S1):p15. doi: 10.1186/2052-3211-8-s1-p15, PMCID 4602184.
31. Lakkis MM. Global and regional drug regulatory harmonization initiatives. Drug Inf J. 2010 May 1;44(3):289-97. doi: 10.1177/009286151004400311.
32. Wong H. The case for compulsory licensing during COVID-19. J Glob Health. 2020 Jun;10(1):010358. doi: 10.7189/jogh.10.010358, PMID 32509289, PMCID 7242884.
33. Pogge T. Just rules for innovative pharmaceuticals. Philosophies. 2022 Jul 12;7(4):79. doi: 10.3390/philosophies7040079.
34. Nwoke J. Regulatory compliance and risk management in pharmaceuticals and healthcare. Int J Health Sci. 2024 Sep 8;7(6):60-88. doi: 10.47941/ijhs.2223.
35. Djordjevic D, McFadyen A, Anderson JA. Ethical challenges and opportunities in the development and approval of novel therapeutics for rare diseases. J Med Access. 2023 Jun 6;7:27550834231177507. doi: 10.1177/27550834231177507, PMID 37323852.
36. Avhad PA, Chalikwar SS, Bhairav BA. A comprehensive review on complex generics. Bull of the Kar Univ. ‘Bio Med Geo’ Ser. BMG. 2022 Mar 30;105(1):129-35. doi: 10.31489/2022bmg1/129-135.
37. Sarikhani Y, Bastani P, Ahmadzadeh M, Dorosti H, Sara JA. Challenges of pharmaceutical supply chain in a developing country: a qualitative study. Thai J Pharm Sci. 2025;43(3):179-85. doi: 10.56808/3027-7922.3049.
38. Haq I, Muselemu OM. Blockchain technology in pharmaceutical industry to prevent counterfeit drugs. IJCA. 2018 Mar 19;180(25):8-12. doi: 10.5120/ijca2018916579.
39. Patil S, Kumar S, Rao DM, Rewatkar KG. Current regulatory framework and challenges for the approval of complex generics in the US and the EU CIS. 2024 Jan 30;2:e2210299X269535. doi: 10.2174/012210299x269535231203164108.
40. Lionberger RA. FDA Critical path initiatives: opportunities for generic drug development. AAPS J. 2008 Feb 20;10(1):103-9. doi: 10.1208/s12248-008-9010-2, PMID 18446510.
41. Van Der Pol KH Van Der, Aljofan M, Blin O, Cornel JH, Rongen GA, Woestelandt AG. Drug repurposing of generic drugs: challenges and the potential role for government. Appl Health Econ Health Policy. 2023 Jul 3;21(6):831-40. doi: 10.1007/s40258-023-00816-6, PMID 37398987.
42. Jayachandran P. Advances in quantitative methods and modeling for complex generic drugs and opportunities to hybridize learnings between innovator and generic drug developers. CPT Pharmacometrics Syst Pharmacol. 2023 Apr 27;12(5):549-51. doi: 10.1002/psp4.12968, PMID 37113050.
43. Lee CY, Chen X, Romanelli RJ, Segal JB. Forces influencing generic drug development in the United States: a narrative review. J Pharm Policy Pract. 2016 Sep 22;9(1):26. doi: 10.1186/s40545-016-0079-1, PMID 27688886.
44. Sreedevi A, Musmade PB, Bhat K, Dharmagadda S, Janodia MD, Bhat BB. A deep dive into the development of complex generics: a comprehensive review. J Appl Pharm Sci. 2024 Oct;14(10):1-14. doi: 10.7324/japs.2024.204337.
45. Raw AS, Wu L. Scientific considerations in the approval of complex generics. In: Sasisekharan R, Lee SL, Rosenberg A, Walker LA, editors. The science and regulations of naturally derived complex drugs. Cham: Springer International Publishing; 2019. p. 157-73. doi: 10.1007/978-3-030-11751-1_9.
46. Chhabra H, Mouslim MC, Kashiramka S, Rathore AS. Dynamics of biosimilar uptake in emerging markets. Expert Opin Biol Ther. 2022 Jun;22(6):679-88. doi: 10.1080/14712598.2022.2076557, PMID 35535988.
47. Ahmad PA, IA, Dehury RK, Behera MR. Access to essential medicines in India: the role of innovations, patents and intellectual property rights. Asia Pac J Health Manag. 2024;19(3):1-8. doi: 10.24083/apjhm.v19i3.1697.
48. Delgado Herrera L, Boone N, Kannenberg J, Van Gelderen M, Ogawa K, Beth Blauwet M. Enhanced globalization and speed to market for innovative medicines. ACCTRA. 2015;2(3):176-85. doi: 10.2174/2213476X03666160127001615.
49. Nakashima A, Kodama K, Sengoku S. Strategic trends of pharmaceutical companies: a growth model through regional focus and inter-regional alliances. Drug Discov Today. 2023 Jul;28(7):103611. doi: 10.1016/j.drudis.2023.103611, PMID 37164307.
50. Pathak R, Gaur V, Sankrityayan H, Gogtay J. Tackling counterfeit drugs: the challenges and possibilities. Pharmaceut Med. 2023 Jul;37(4):281-90. doi: 10.1007/s40290-023-00468-w, PMID 37188891.
51. Bakkert Hart IM, Ohana D, Venhuis BJ. Current challenges in the detection and analysis of falsified medicines. J Pharm Biomed Anal. 2021 Apr 15;197:113948. doi: 10.1016/j.jpba.2021.113948, PMID 33582458.
52. Vinothkumar V, Prabhu Kumar A. Speed of new product development enhancement through supply chain management in a generic pharmaceutical company. Int J Manag Stud. 2018 Apr 1;52(3):109. doi: 10.18843/ijms/v5i2(3)/14.
53. Mhando F, Berenge HT, Yue J, Gao L, Makundi EA, Malebo HM. Challenges and solutions for local pharmaceutical production in Tanzania. Voice Publ. 2025 Jan 1;11(2):318-31. doi: 10.4236/vp.2025.112023.
54. Pezzola A, Sweet CM. Global pharmaceutical regulation: the challenge of integration for developing states. Global Health. 2016 Dec 20;12(1):85. doi: 10.1186/s12992-016-0208-2, PMID 27998293.
55. Bansal S, Mahendiratta S, Kumar S, Sarma P, Prakash A, Medhi B. Collaborative research in modern era: need and challenges. Indian J Pharmacol. 2019 May-Jun;51(3):137-9. doi: 10.4103/ijp.IJP_394_19, PMID 31391680.
56. O Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021 Aug 1;336:144-58. doi: 10.1016/j.jconrel.2021.06.017, PMID 34126170.
57. Vieira M, Andia T, Karim O, Srishti SA, Pineda SA, Alonso Ruiz A. Rising pharmaceutical innovation in the Global South: a landscape study. J Pharm Policy Pract. 2023 Nov 27;16(1):155. doi: 10.1186/s40545-023-00669-3, PMID 38012700, PMCID PMC10680326.
58. Pava ML, Tucker EL. Effects of geopolitical strain on global pharmaceutical supply chain design and drug shortages. arXiv; 2023 Jan 1. doi: 10.48550/arxiv.2308.07434.
59. US Food and Drug Administration. Drug Supply Chain Security Act (DSCSA): law and policies. Silver Spring (MD): US Food and Drug Administration. Available from: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/drug-supply-chain-security-act-law-and-policies.
60. Sivaraman A, Banga A. Quality by design approaches for topical dermatological dosage forms. RRTD. 2015;4:9-21. doi: 10.2147/RRTD.S82739.
61. Gordon J, Potthast H, Stahl M, Rago L. World health organisation (WHO). In: Kanfer I, editor. Bioequivalence requirements in various global jurisdictions. Cham: Springer International Publishing. 2017. p. 307-31. doi: 10.1007/978-3-319-68078-1_11.
62. Merchant HA, Babar ZU, Hussain IM. A leap towards enforcing medicines prescribing by generic names in low and middle-income countries (LMICs): pitfalls limitations and recommendations for local drug regulatory agencies. J Pharm Policy Pract. 2022 Dec 22;15(1):104. doi: 10.1186/s40545-022-00501-4, PMID 36550588.
63. Hassen HK, Mekasha YT, Tegegne AA, Ozalp Y. A narrative review on problems in product quality regulatory system constraints and the concept of quality by design as a solution for quality assurance of African medicines. Front Med (Lausanne). 2024 Oct 3;11:1472495. doi: 10.3389/fmed.2024.1472495, PMID 39421861.
64. Franco P, Jain R, Rosenkrands Lange E, Hey C, Koban MU. Regulatory pathways supporting expedited drug development and approval in ICH member countries. Ther Innov Regul Sci. 2022;57(3):484-514. doi: 10.1007/s43441-022-00480-3, PMID 36463352.
65. K CP, MP, SA, RS. Concept of 505 (b) (2) application: benefits and challenges. Int J Drug Reg Affairs. 2018;2(2):16-20. doi: 10.22270/ijdra.v2i2.127.
66. Salminen WF, Wiles ME, Stevens RE. Streamlining nonclinical drug development using the FDA 505(b) (2) new drug application regulatory pathway. Drug Discov Today. 2018;24(1):46-56. doi: 10.1016/j.drudis.2018.07.005, PMID 30041014.
67. US Food and Drug Administration. Pre‑ANDA Program; 2022. Available from: https://www.fda.gov/drugs/generic‑drugs/pre‑anda‑program.
68. Nahler G. Dictionary of Pharmaceutical Medicine. Wien: Springer‑Verlag; 2009. p. 48. doi: 10.1007/978-3-211-89836-9_363.
69. Sullivan JO, Blake K, Berntgen M, Salmonson T, Welink J, Pharmacokinetics Working Party. Overview of the European medicines agencys development of product-specific bioequivalence guidelines. Clin Pharmacol Ther. 2018;104(3):539-45. doi: 10.1002/cpt.957, PMID 29319156.
70. Generic Applications in the EU, Patents and Exclusivity; 2011. Available from: https://gabionline.net/reports/generic-applications-in-the-eu-patents-and-exclusivity. [Last accessed on 10 Nov 2025].
71. Ellen FM, Pascale Boulet, Brook K Baker. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: a proposal for greater coherence in European pharmaceutical legislation. J Pharm Policy Pract. 2017;10(1):19. doi: 10.1186/s40545-017-0107-9, PMID 28670455.
72. Dansie LS, Odoch WD, Ardal C. Industrial perceptions of medicines regulatory harmonization in the East African community. PLOS One. 2019;14(6):e0218617. doi: 10.1371/journal.pone.0218617, PMID 31216323.
73. Patel BD, Suthar SP, Mansuri AM, Joshi VD. A comparative analysis of generic drug assessment and regulatory approval in the USA, Europe and India. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024;40:e20240029. doi: 10.62958/j.cjap.2024.029, PMID 39384543.
74. Chakraborty K, Yadav K. Drug approval process in US, Europe and India and its regulatory requirements: a review. Int J Drug Regul Aff. 2018;6(3):31. doi: 10.22270/ijdra.v6i3.266.
75. Ramteke A, Sufi MB, Deolekar R, Pathik C. A review on CDSCO: Central Drug Standard Control Organisation. IJARSCT. 2023;3(1):569-71. doi: 10.48175/ijarsct-14084.
76. RA, VG, Nelavala A. Analysis of regulatory strategies for generic product approval across Asian nations. Int JExp Biomed Res. 2024;3(1):16-22. doi: 10.26452/ijebr.v3i1.557.
77. Kannappan S, Darrow JJ, Kesselheim AS, Beall RF. The timing of 30 m stay expirations and generic entry: a cohort study of first generics, 2013-2020. Clin Transl Sci. 2021 Sep;14(5):1917-23. doi: 10.1111/cts.13046, PMID 33982425.
78. US Food and Drug Administration. GDUFA III user fee resource management program. Silver Spring (MD): FDA. Available from: https://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-iii-user-fee-resource-management-program. [Last accessed on 11 Nov 2025].
79. Melocchi A, Briatico Vangosa F, Uboldi M, Parietti F, Turchi M, Von Zeppelin D. Quality considerations on the pharmaceutical applications of fused deposition modeling 3D printing. Int J Pharm. 2021 Jan 5;592:119901. doi: 10.1016/j.ijpharm.2020.119901, PMID 33010399.
80. Ngum N, Ndomondo Sigonda M, Walker S, Salek S. Regional regulatory harmonisation initiatives: their potential contribution to the newly established African medicines agency. Regul Toxicol Pharmacol. 2023;145:105497. doi: 10.1016/j.yrtph.2023.105497, PMID 37778434.
81. The FDA Group. Abbreviated New Drug Applications (ANDA) explained: a quick-guide. Boston (MA): The FDA Group; 2023 July 12. Available from: https://www.thefdagroup.com/blog/abbreviated-new-drug-applications-anda.
82. Drug patent watch-transform data into market domination; 2025. Available from: https://www.drugpatentwatch.com/blog/the-505b2-drug-patent-approval-process-uses-and-potential-advantages/?srsltid=AfmBOoqhq-3KJFTul2nYz9IoKxsKEn9INRXIaMX1IWx35Sy0bwmlCd.
83. Aggarwal S & Associates. Generic drug assessment and approval process in India; 2025 June 16. Available from: https://aggarwalsandassociates.com/generic-drug-assessment-and-approval-process-in-india/. [Last accessed on 11 Nov 2025].
84. Zoman SS, Khokale A. Regulatory frameworks adopted by the US and EU for bringing complex generics in the market. J Chem Health Risks. 2024;14(6):1187-96.
85. Bhatt M, Tank S, Shah J, Maheshwari D. Regulatory framework and disparities of complex generics in United States, European Union and Latin America. Journal of Generic Medicines. 2023;19(3):130-40. doi: 10.1177/17411343231194755.
86. Pribluda VS, Koduri C, Ibrahim S, Blake KV. Expanding global access to complex generics: the case for regulatory convergence. Regulatory Affairs Professionals Society; 2025. Available from: https://media.raps.org/m/55966497433bd03/original/25-2_pribluda-et-al.pdf. [Last accessed on 10 Nov 2025].
87. Raval P, Patel K, Patel K, Patel A, Gupta M, Bodhe S. An overview on comparative study of generic drug approval process in USA, India and Australia. Int J Pharmacol Res. 2025;31(1):1.
88. Xu W. A research on the influence of college student time management on their academic development. In: Proceedings of the 2020 5th International Conference on Modern Management and Education Technology (MMET 2020). Paris, France: Atlantis Press; 2020. p. 104-9. doi: 10.2991/assehr.k.201023.019.
89. Weaver P. The origins of modern management. South Melbourne (VIC): Mosaic Project Services Pty Ltd; 2007. Available from: https://mosaicprojects.com.au/pdf_papers/p050_origins_of_modern_management.pdf. [Last accessed on 10 Nov 2025].
90. Kwak YH. Brief history of project management; 2023. Available from: http://home.gwu.edu/~kwak/PM_History.pdf. [Last accessed on 10 Nov 2025].
91. Luthy C. The late origins of the timeline or: three paradoxes explained. Ann Sci. 2024;82(1):1-43. doi: 10.1080/00033790.2023.2289524, PMID 38308816.
92. Pamuji S, Baharuddin KM, Novianto AY, Kasmin K, Wibowo EP. Time management: the key to success in managing complex projects. J Markcount Finance. 2024;2(3):361-70. doi: 10.70177/jmf.v2i3.1470.
93. Gupta G, Mahor R, Pawar N, Gumashta R, Gumashta J. Program management challenges of clinical studies: a qualitative critical assessment. J Family Med Prim Care. 2023 Apr 1;12(4):625-31. doi: 10.4103/jfmpc.jfmpc_1151_22, PMID 37312779.
94. Khan UU, Ali Y, Garai Fodor M, Csiszarik Kocsir A. Application of project management techniques for timeline and budgeting estimates of startups. Sustainability. 2023 Nov 1;15(21):15526. doi: 10.3390/su152115526.
95. Poskett J. The history of science the ‘big picture’ and the politics of scale. BJHS Themes. 2024 Dec 1;9:1-15. doi: 10.1017/bjt.2024.24.
96. Lehtinen TO, Itkonen J, Lassenius C. Recurring opinions or productive improvements-what agile teams actually discuss in retrospectives. Empir Software Eng. 2016 Nov 3;22(5):2409-52. doi: 10.1007/s10664-016-9464-2.
97. Wong AK, Mooghali M, Ramachandran R, Ross JS, Wallach JD. Use of expedited regulatory programs and clinical development times for FDA-approved novel therapeutics. JAMA Netw Open. 2023 Aug 31;6(8):e2331753. doi: 10.1001/jamanetworkopen.2023.31753, PMID 37651145.
98. Bussgen M, Bussgen MA. Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades. J Pharm Policy Pract. 2023 Sep 28;16(1):109. doi: 10.1186/s40545-023-00612-6, PMID 37770995.
99. Souza FB, Moraes AA. Analise da aplicacao da gestao de projetos por corrente critica no processo de desenvolvimento de produtos e na gestão de portfolio de um fabricante de aeronaves. Gest Prod. 2016 Aug 25;23(3):473-85. doi: 10.1590/0104-530x1953-15.
100. Yang S, Hu X, Zhu J, Zheng B, Bi W, Wang X. Aspects and implementation of pharmaceutical quality by design from conceptual frameworks to industrial applications. Pharmaceutics. 2025;17(5):623. doi: 10.3390/pharmaceutics17050623, PMID 40430914.
101. Stewart S, Giambalvo J, Vance J, Faludi J, Hoffenson S. A product development approach advisor for navigating common design methods, processes and environments. Designs. 2020 Feb 14;4(1):4. doi: 10.3390/designs4010004.
102. Kuwashima K. Exploring the characteristics of pharmaceutical product development. Annals Bus Admin Sci. 2015 Jun 14;14(3):161-70. doi: 10.7880/abas.14.161.
103. Yang C, Deng B, Wen Q, Guo P, Liu X, Wang C. Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database. Front Pharmacol. 2025 Feb 10;16:1548376. doi: 10.3389/fphar.2025.1548376, PMID 39995419.
104. Reddy MV, Ganesh GN, Ahmed SS, Rajendra PK, Babu E. Research on pharmaceutical product life cycle management challenges faced by generic manufacturers for US approval. Indian J Pharm Educ Res. 2022 Apr 1;56(2 Suppl):s347-55. doi: 10.5530/ijper.56.2s.105.
105. Berger J, Dunn JD, Johnson MM, Karst KR, Shear WC. How drug life-cycle management patent strategies may impact formulary management. Am J Manag Care. 2016 Oct 1;22(16 Suppl):S487-95. PMID 28719222.
106. Lehmann S, Allard R, Boehler Y. The European Medicines Agency clinical data website enables insights into clinical development timelines and strategy. Open Access J Clin Trials. 2019 Oct 15;11:37-56:S205842. doi: 10.2147/OAJCT.
107. Hasan MI, Shimu SA, Akther A, Jahan I, Hamiduzzaman M, Hasan AH. Development of generic drug products by pharmaceutical industries considering regulatory aspects: a review. J Biosci Med. 2021 Jan 1;9(10):23-39. doi: 10.4236/jbm.2021.910003.
108. Pramod K, Tahir MA, Charoo NA, Ansari SH, Ali J. Pharmaceutical product development: a quality by design approach. Int J Pharm Investig. 2016;6(3):129-38. doi: 10.4103/2230-973x.187350, PMID 27606256, PMCID 4991121.
109. Reddy MV, Ganesh G, Babu B, Jagadeesan R, Mr PK. Risk assessment of failures in generic drug development and approval procedure under competitive generic drug therapy and patent challenge exclusivities provided by the United States food and Drug Administration. Acta Marisiensis Seria Medica. 2022 Mar 1;68(1):28-34. doi: 10.2478/amma-2022-0004.
110. Hao L, Zhang J, Ma X. Development trend of software process model. IOP Conf Ser: Mater Sci Eng. 2019;569(5):052077. doi: 10.1088/1757-899x/569/5/052077.
111. Amaral C, Rodrigues AR, Veiga F, Bell V. Biosimilar medicines: from development process to marketing authorization by the EMA and the FDA. Appl Sci. 2024;14(17):7529. doi: 10.3390/app14177529.
112. Micic L. Agile methodology selection criteria: IT start-up case study. IOP Conf Ser: Mater Sci Eng. 2017 May 1;200:012031. doi: 10.1088/1757-899x/200/1/012031.
113. Veiga AP. Project success in agile development projects. arXiv; 2017 Jan 1. doi: 10.48550/arxiv.1711.06851.
114. Lodha A. Agile: open innovation to revolutionize pharmaceutical strategy. Imperial J Interdiscip Res. 2016;2(12):39-41.
115. Alsaadi M, Lisitsa A, Khalaf M, Qasaimeh M. Investigating the capability of agile processes to support medical devices regulations: the case of XP, scrum, and FDD with EU MDR regulations. In: Huang DS, Huang ZK, Hussain A, editors. Intelligent computing methodologies: 15th International Conference, ICIC 2019, Nanchang, China, August 3-6, 2019, proceedings, part III. Cham: Springer International Publishing; 2019. p. 581-92. doi: 10.1007/978-3-030-26766-7_53.
116. Kaur K, Jajoo A, Manisha. Applying agile methodologies in industry projects: benefits and challenges. In: Proceedings of the 2015 International Conference on Computing Communication Control and Automation (ICCUBEA) Pune, India; 2015 Feb 1. p. 832‑6. doi: 10.1109/ICCUBEA.2015.166.
117. Heimicke J, Chen R, Albers A. Agile meets plan-driven hybrid approaches in product development: a systematic literature review. Proc Des Soc: Des Conf. 2020 May 1;1:577-86. doi: 10.1017/dsd.2020.259.
118. Minghetti P, Musazzi UM, Casiraghi A, Rocco P. Old active ingredients in new medicinal products: is the regulatory path coherent with patients expectations. Drug Discov Today. 2020 Aug;25(8):1337-47. doi: 10.1016/j.drudis.2020.05.013, PMID 32485225.
119. Li EC, Abbas R, Jacobs IA, Yin D. Considerations in the early development of biosimilar products. Drug Discov Today. 2015;20Suppl2:1-9. doi: 10.1016/j.drudis.2014.12.017, PMID 25572407.
120. Cristofoletti R, Schmidt S, Diniz A. Non-procrustean pathways for complex generic drugs development. Ther Deliv. 2018 Sep 1;9(9):605-7. doi: 10.4155/tde-2018-0047, PMID 30189807.
121. Remington K, Pollack J. Tools for complex projects. Vol. 1. London: Routledge; 2016. doi: 10.4324/9781315550831.
122. Dobre OI. Differences of organizational culture between small and large enterprises. Ovidius University Annals Economic Sciences Series. 2016;16(1):296-301.
123. Nazarian A, Atkinson P. Organisational size as a moderator of the culture-effectiveness relationship: the case of the private sector in Iran. Organ Cult Int J. 2015 Jul 9;14(2):1-16. doi: 10.18848/2327-8013/CGP/v14i02/50951.
124. Genedy M, Hellerstedt K, Naldi L, Wiklund J. Growing pains in scale-ups: how scaling affects new venture employee burnout and job satisfaction. J Bus Venturing. 2023 Nov 22;39(2):106367. doi: 10.1016/j.jbusvent.2023.106367.
125. Yasar H, Sagsan M. The mediating effect of organizational stress on organizational culture and time management: a comparative study with two universities. Sage Open. 2020 Apr 1;10(2):1-11. doi: 10.1177/2158244020919507.
126. Maqsoom A, Choudhry RM, Umer M, Mehmood T. Influencing factors indicating time delay in construction projects: impact of firm size and experience. Int J Constr Manag. 2019 May 9;21(12):1251-62. doi: 10.1080/15623599.2019.1613206.
127. Van Neerijnen P Van, Figge P, Tempelaar MP, Schippers MC. Ambidexterity: size matters, reflexive climate and organizational TMS’s influence and the contingent effect of size. J Small Bus Manag. 2021 Oct 21;61(6):3121-54. doi: 10.1080/00472778.2021.1981917.
128. Shayegan S, Yavari N, Bazrkar A. Human resource development practices and organizational performance: examining the mediating role of transformational leadership style. Work Pap Oper Manag. 2022 Jul 5;13(2):64-85. doi: 10.4995/wpom.17243.
129. Tang J, Yang J, Ye W, Khan SA. Now is the time: the effects of linguistic time reference and national time orientation on innovative new ventures. J Bus Venturing. 2021 Aug 9;36(5):106142. doi: 10.1016/j.jbusvent.2021.106142.
130. Malmi T, Bedford DS, Bruhl R, Dergard J, Hoozee S, Janschek O. The use of management controls in different cultural regions: an empirical study of anglo-saxon germanic and nordic practices. J Manag Control. 2022 Jul 3;33(3):273-334. doi: 10.1007/s00187-022-00342-x.
131. Huang J. The challenge of multicultural management in global projects. Procedia Soc Behav Sci. 2016 Jul 1;226:75-81. doi: 10.1016/j.sbspro.2016.06.164.
132. Islam MS, Trigunarsyah B. Construction delays in developing countries: a review. J Constr Eng Proj Manag. 2017;7(1):1-12. doi: 10.6106/jcepm.2017.3.30.001.
133. Khan MA, Panarina E. The role of national cultures in shaping the corporate management cultures: a four-country theoretical analysis. JEECAR. 2017 Apr 25;4(1):25. doi: 10.15549/jeecar.v4i1.152.
134. Huang H. Research on the importance of cross-cultural integration in international business management. Mod Econ Manag Forum. 2023 Dec 26;4(6):171. doi: 10.32629/memf.v4i6.1502.
135. Starkey K, Starkey K. Time and work: a psychological perspective. In: Blyton P, Hassard J, Hill S, Starkey K, editors. Time. Time, work and organization. London: Routledge; 2017. p. 35-56. doi: 10.4324/9781315267272-3.
136. Sayfudinova NZ, Nagumanova AI. Influence of psychological factors on the success of an organization and management activities. Ekonomika i Upravlenie: Problemy Resheniya. 2024 Jan 1;4/7(145):79-83. doi: 10.36871/ek.up.p.r.2024.04.07.012.
137. Kumari N. Increasing employees efficiency through workforce management. JBTP. 2023;11(3):77. doi: 10.22158/jbtp.v11n3p77.
138. Amritharaj SD. Role of psychology in human resource management. Int J Res Hum Resour Manage. 2019;1(1):17-20. doi: 10.33545/26633213.2019.v1.i1a.5.
139. Romero Perez C, Sanchez Lissen E. Scientific narratives in the study of student time management: a critical review. RIMCIS. 2022;11(2):60-86. doi: 10.17583/rimcis.10322.
140. Voskoboynikov F. In: Dalcher D, editor. Managing projects in a world of people, strategy and change. London: Routledge; 2018. p. 39-44. doi: 10.4324/9780429449741-5.
141. Jeyabharathy DP. Psychological dimensions of time management among employees. IJSREM. 2023 Jan 5;7(1):1-5. doi: 10.55041/ijsrem17408.
142. Schuhmacher A, Hinder M, Von Stegmann Und Stein A, Hartl D, Gassmann O. Analysis of pharma R&D productivity a new perspective needed. Drug Discov Today. 2023;28(10):103726. doi: 10.1016/j.drudis.2023.103726, PMID 37506762.
143. Parpiev K. Overemphasis on hierarchy and bureaucracy leading to slow decision-making and a lack of agility; 2023 Jan 1. doi: 10.2139/ssrn.4361544.
144. Murthy NN, Nagaraja HN, Rikhtehgar Berenji HR. Managing concurrency in cyclical projects under stochastic task environments: vaccine development projects during pandemics. Prod Oper Manag. 2022 Nov 9;32(3):951. doi: 10.1111/poms.13907, PMID 36718233.
145. Aeon B, Faber A, Panaccio A. Does time management work. A meta-analysis. PLOS One. 2021;16(1):e0245066. doi: 10.1371/journal.pone.0245066, PMID 33428644.
146. Rajesh E, Lal R, Mathuraswamy P, Ahamed SBI, Gaidhani S. Motivational theories and their applicability in the workplace. Journal of Informatics Education and Research. 2024 Jan 1;4(2):3111-7. doi: 10.52783/jier.v4i2.1225.
147. Yesudas R, Castelle K, Joiner KF, Bradley JM, Efatmaneshnik M. Addressing tensions of overlapping project management and systems engineering with the elegance of a complex systems governance approach. Int J Syst Syst Eng. 2020 Jan 1;10(2):164. doi: 10.1504/ijsse.2020.109143.
148. Ewim CP, Achumie GO, Adeleke AG, Okeke IC, Mokogwu C. Developing a cross-functional team coordination framework: a model for optimizing business operations. Int J Frontline Res Multidiscip Studies. 2024 Oct 9;4(1):15-34. doi: 10.56355/ijfrms.2024.4.1.0030.
149. Watanabe WC, Shafiq M, Nawaz MJ, Saleem I, Nazeer S. The impact of emotional intelligence on project success: mediating role of team cohesiveness and moderating role of organizational culture. Int J Eng Bus Manag. 2024 Mar 5;16:18479790241232508. doi: 10.1177/18479790241232508.
150. Luckmann P, Laumann M. How national culture impacts the success of project customer engagement: an empirical investigation. Procedia Comput Sci. 2016 Jan 1;100:95-102. doi: 10.1016/j.procs.2016.09.128.
151. Zhang Y, Marquis C, Filippov S, Haasnoot HJ, Van Der Steen M. The challenges and enhancing opportunities of global project management: evidence from Chinese and Dutch cross-cultural project management. SSRN Electron J. 2015 Jan 1. doi: 10.2139/ssrn.2807439.
152. Abu Rumman MA, Alzeyadat AA. The influence of delegation of authority and management control on the effectiveness of managerial decision-making in the Arab pharmaceutical manufacturing company limited in Al-Salt City in Jordan. Int J Bus Admin. 2019;10(4):13. doi: 10.5430/ijba.v10n4p13.
153. Malik TH. Culturally imprinted anxiety and the itinerary of clinical trial projects for its management. Cross-Cult Res J Comp Soc Sci. 2021;55(2-3):148-78. doi: 10.1177/1069397120967309.
154. Oyekunle D, Amodu O, Lateef O. Cultural dynamics in UK project environments: exploring the impact of individualistic and collectivist cultures on project outcomes. OALib. 2024;11(5):1-21. doi: 10.4236/oalib.1111573.
155. Boubakri N, Chkir I, Saadi S, Zhu H. Does national culture affect corporate innovation? International evidence. J Corp Fin. 2021;66:101847. doi: 10.1016/j.jcorpfin.2020.101847.
156. Piwowar Sulej K. Organizational culture and project management methodology: research in the financial industry. Int J Manag Projects Bus. 2021 Mar 30;14(6):1270-89. doi: 10.1108/ijmpb-08-2020-0252.
157. Reitzig M. How to get better at flatter designs: considerations for shaping and leading organizations with less hierarchy. J Organ Des. 2022 Jan 27;11(1):5-10. doi: 10.1007/s41469-022-00109-7.
158. Beer R, Qi A, Rios I. Team building and incentive schemes in collaborative projects; 2024 Jan 1. p. 47. doi: 10.2139/ssrn.4872792.
159. Basten D, Muller M, Ott M, Pankratz O, Rosenkranz C. Impact of time pressure on software quality: a laboratory experiment on a game-theoretical model. PLOS One. 2021 Jan 15;16(1):e0245599. doi: 10.1371/journal.pone.0245599, PMID 33449957.
160. Furxhi G. Employee’s resistance and organizational change factors. EJBMR. 2021 Mar 12;6(2):30-2. doi: 10.24018/ejbmr.2021.6.2.759.
161. De Waal AA De, De Boer FA De. Project management control within a multicultural setting. J Strategy Manag. 2017 Mar 27;10(2):148-67. doi: 10.1108/jsma-03-2016-0020.
162. Liu C. Employee performance in multinational corporations: the impact of cross-cultural training in the globalized era. EHSS. 2024 Apr 19;29:338-43. doi: 10.54097/z8s79850.
163. Iqbal M, Suzianti A. Improvement of new product development process by evaluating the existing development approach: lesson learned from pharmaceutical and ICT companies. AIP Conf Proc. 2020 Jan 1;2227:040009. doi: 10.1063/5.0001007.
164. Suvvari SK. Project portfolio management: best practices for strategic alignment. Int J Prof Bus Rev. 2023 Dec 29;8(12):e04987. doi: 10.26668/businessreview/2023.v8i12.4987.
165. Kummer TF, Schmiedel T. Reviewing the role of culture in strategic information systems research: a call for prescriptive theorizing on culture management. Commun Assoc Inf Syst. 2016;38:122-44. doi: 10.17705/1cais.03805.
166. Chang MH. Research on modern corporate cost management and cost control methods. Int J Glob Econ Manag. 2024 Apr 25;2(3):320-6. doi: 10.62051/IJGEM.v2n3.38.
167. Vinayavekhin S, Phaal R. Improving synergy in strategic planning: enablers and synchronization assessment framework (SAF). Int J Innov Technol Manag. 2020 Jan 31;17(2):2050009. doi: 10.1142/s0219877020500091.
168. Lopez D, Oliver M. Integrating innovation into business strategy: perspectives from innovation managers. Sustainability. 2023 Apr 11;15(8):6503. doi: 10.3390/su15086503.
169. Mwaikambo L, Brittingham S, Ohkubo S, Salem RM, Sama DJ, Sow F. Key factors to facilitate locally driven family planning programming: a qualitative analysis of urban stakeholder perspectives in Africa and Asia. Global Health. 2021 Jul 3;17(1):75. doi: 10.1186/s12992-021-00717-0, PMID 34217354, PMCID 8254949.
170. Akroyd C, Biswas SS, Chuang S. How management control practices enable strategic alignment during the product development process. Adv Manag Acc. 2016. p. 99-138. doi: 10.1108/s1474-787120150000026004.
171. Sunmola HO. Evaluation of motivating and requiring factors for milestones in IT projects. Procedia Manuf. 2020;51:1469-77. doi: 10.1016/j.promfg.2020.10.204.
172. Ojra J, Opute AP, Alsolmi MM. Strategic management accounting and performance implications: a literature review and research agenda. Future Bus J. 2021;7(1):64. doi: 10.1186/s43093-021-00109-1.
173. Zhang W, Zeng X, Liang H, Xue Y, Cao X. Understanding how organizational culture affects innovation performance: a management context perspective. Sustainability. 2023 Apr 14;15(8):6644. doi: 10.3390/su15086644.
174. Menon S. Best practices and implementation challenges in effective project management. Int Bus Res. 2024 Mar 27;17(2):66. doi: 10.5539/ibr.v17n2p66.
175. Wegrecka Chudzik K, Jankowski L, Duda J. Evolving role of PMO in contemporary project management. Commun Int Proc. 2024 Jan 1;2024(5). doi: 10.5171/2024.4343524.
176. Szekely B, Kesmarki Gally SE, Lakner Z. Hybrid Project Management: scoping review. Proj Leadersh Soc. 2025 Mar 1;6:100182. doi: 10.1016/j.plas.2025.100182.
177. Misbahuddin M, Maarif MS. The linkage between leadership style of project manager and project performance: evidence from the telecommunication industry. 2024 Jan 1;9(3):163-82. doi: 10.5267/j.jpm.2024.6.001.
178. Bolanowski M, Ganzha M, Maciaszek L, Paprzycki M, Slezak D, editors. Proceedings of the 19th Conference on Computer Science and Intelligence System, Warsaw, Poland. ACSIS; 2024 Oct 23-26;39:429-41.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Murali Mohan Babu, Ni Luh Putu Nurshanti, Harry Martha Wijaya, Raymond R. Tjandrawinata
This work is licensed under a Creative Commons Attribution 4.0 International License.